When comparing Liposomal Urolithin A vs Regular Urolithin A, the key question is not simply which form sounds more advanced. Buyers need to know how each form is made, how much active Urolithin A it delivers, whether it remains stable, and what evidence supports its absorption and benefits. Regular Urolithin A currently has the stronger base of published human research. Liposomal Urolithin A offers promising formulation advantages, but its performance depends on the exact delivery system and should be supported by product-specific characterization, stability, and pharmacokinetic data.
Urolithin A is a metabolite formed when certain gut microorganisms convert ellagitannins and ellagic acid from foods such as pomegranates, berries, and walnuts. Because natural conversion varies considerably among individuals, direct supplementation provides a more consistent means of achieving Urolithin A exposure (Cerdá et al., 2005; Singh et al., 2022a). Provita is the leading urolithin A supplier in China, exporting 200 tons of bulk liposomal urolithin A powder and wholesale regular urolithin A powder, with OEM services such as capsules, tablets, custom private labels, etc.
This article compares regular and liposomal Urolithin A by composition, bioavailability, clinical evidence, dosage, quality control, stability, cost, and formulation suitability.
Quick Answer: Is Liposomal Urolithin A Better?
Not necessarily. A properly developed liposomal formulation may improve the dispersion, digestive stability, or absorption of Urolithin A. However, a “liposomal” label alone does not prove greater bioavailability or better health outcomes.
Published human trials have shown that regular oral Urolithin A is absorbed and can affect biomarkers associated with mitochondrial and muscle health. Research on Urolithin A liposomes is promising, but it consists mainly of formulation, simulated-digestion, cell, and animal studies. As of July 2026, we did not identify a published human trial directly comparing liposomal Urolithin A with an equivalent dose of regular Urolithin A.
The practical conclusion is straightforward:
- Choose regular Urolithin A when human evidence, formulation simplicity, and cost control are the priorities.
- Consider liposomal Urolithin A when a supplier can document the active dose, vesicle structure, encapsulation efficiency, particle characteristics, digestive stability, and finished-product shelf life.
- Do not assume a lower liposomal dose is equivalent to a higher regular dose without comparative human pharmacokinetic data.
Liposomal Urolithin A vs Regular Urolithin A at a Glance
| Comparison point | Regular Urolithin A | Liposomal Urolithin A |
|---|---|---|
| Basic form | Purified, non-liposomal Urolithin A | Urolithin A associated with phospholipid vesicles |
| Water dispersibility | Generally limited | Potentially improved |
| Human clinical evidence | Multiple published studies | Limited formulation-specific human evidence |
| Preclinical evidence | Established oral exposure | Promising formulation and animal data |
| Manufacturing complexity | Lower | Higher |
| Required quality tests | Identity, assay, purity, impurities, contaminants, stability | Standard tests plus particle size, PDI, encapsulation, phospholipids, leakage, and vesicle stability |
| Stability risks | Moisture, light, heat, and interaction with other ingredients | Aggregation, leakage, lipid oxidation, hydrolysis, and particle-size drift |
| Dose interpretation | Usually milligrams of active Urolithin A | May mean active Urolithin A or total liposomal complex |
| Cost | Usually lower | Usually higher |
| Best-supported advantage | Direct human evidence | Potential delivery and product-format advantages |
What Is Regular Urolithin A?
Regular Urolithin A is purified Urolithin A supplied without a liposomal carrier. It may also be described as standard, free-form, conventional, or non-liposomal Urolithin A. These are descriptive terms, not official grades.
Regular Urolithin A is commonly supplied as a fine powder for capsules, tablets, sachets, powder blends, gummies, and other dietary supplement formats. It may still be combined with excipients, oils, emulsifiers, or food matrices, so “regular” does not automatically mean poorly formulated.
For commercial production, buyers should begin with a defined specification for identity, assay, HPLC purity, related substances, residual solvents, elemental impurities, microbial quality, water content, and particle size. Provita Biotech supplies high-purity bulk Urolithin A powder for nutraceutical, healthy-aging, and sports nutrition formulations.
Is regular Urolithin A absorbed?
Yes. Human studies show that directly administered Urolithin A produces measurable levels of circulating Urolithin A and its conjugated metabolites. In an early human study, oral Urolithin A was bioavailable at the tested doses and affected plasma acylcarnitines and skeletal-muscle mitochondrial gene expression after repeated intake (Andreux et al., 2019).
Direct supplementation also yielded more consistent exposure than relying on the gut microbiome’s conversion of pomegranate-derived precursors (Singh et al., 2022a). This means liposomal encapsulation is not required for regular Urolithin A to enter the body.
What do human trials show?
Regular Urolithin A has been studied at daily amounts including 500 mg and 1,000 mg. These study doses should not be interpreted as universal recommendations.
In older adults, Liu et al. (2022) reported improvements in muscle-endurance measures and several plasma biomarkers after long-term supplementation. However, the trial did not find significant between-group improvements for its primary outcomes of six-minute walking distance and maximal ATP production. This distinction matters because the evidence is promising but not uniformly positive across every outcome.
In a separate trial involving middle-aged adults, Urolithin A improved certain muscle strength measures and altered biomarkers associated with mitochondrial health. The primary endpoint of peak power output did not improve significantly (Singh et al., 2022b). A 2024 systematic review similarly concluded that human findings are encouraging for selected inflammatory, muscle, and mitochondrial outcomes, while more extensive and longer studies are needed (Hodzic Kuerec et al., 2024).
What Is Liposomal Urolithin A?
Liposomal Urolithin A is a formulation in which Urolithin A is incorporated into or associated with microscopic phospholipid structures called liposomes. A liposome consists of one or more phospholipid bilayers surrounding an aqueous compartment. Depending on the formulation, Urolithin A may be located within the bilayer, inside the vesicle, on its surface, or partly outside the vesicles as free active material.
A liposomal formula may contain:
- Urolithin A
- Phosphatidylcholine
- Sunflower or soy lecithin
- Water or another hydration medium
- Antioxidants and stabilizers
- Cryoprotectants for freeze drying
- Carrier powders for spray drying
- Optional coating materials
Liposomal Urolithin A can be supplied as a liquid dispersion, capsule fill, dry powder, or proliposome. A proliposome is a dry precursor designed to form liposome-like vesicles after hydration.
Liposome vs phospholipid complex
A true liposome has an organized, vesicular phospholipid structure. A phospholipid complex is an association between an active ingredient and phospholipids, but it may not form closed vesicles. A lipid-based powder or lecithin blend is also not automatically a liposome.
Brands should therefore request evidence of vesicle formation instead of relying on marketing terminology. Appropriate data may include particle-size distribution, polydispersity index, microscopy, encapsulation efficiency, and performance after reconstitution.
Why Use Liposomal Delivery for Urolithin A?
Urolithin A has limited water solubility. This may pose challenges related to dispersion, dissolution, sedimentation, dose uniformity, and incorporation into aqueous products. Liposomal delivery is intended to place the active in a phospholipid-based system that may improve its handling and behavior during digestion.
Potential advantages include:
- Improved dispersion in aqueous environments
- Protection from chemical or digestive degradation
- Higher bioaccessibility during digestion
- Increased contact with intestinal surfaces
- Better suitability for liquids and functional beverages
- Taste or appearance improvements in some formulations
- Differentiation for premium supplement products
These are formulation objectives, not guaranteed outcomes. Provita’s custom liposomal delivery technology can be tailored to the active ingredient, target dosage form, processing conditions, and stability requirements.
Solubility, Bioaccessibility, and Bioavailability Are Not the Same
These terms are often used interchangeably in supplement marketing, but they describe different properties.
Solubility
Solubility describes how much Urolithin A can dissolve in a particular medium under defined conditions.
Dispersibility
Dispersibility describes how evenly particles or droplets remain distributed. A cloudy, well-dispersed liquid is not necessarily a molecular solution.
Dissolution rate
Dissolution rate describes how quickly Urolithin A moves from a solid form into a dissolved state.
Bioaccessibility
Bioaccessibility is the proportion released from a product during digestion and made available for intestinal absorption. It is commonly evaluated with simulated gastrointestinal models.
Bioavailability
Bioavailability describes the rate and extent of systemic exposure. Human or animal pharmacokinetic studies may measure area under the concentration-time curve, maximum concentration, time to maximum concentration, half-life, and relevant metabolites.
Bioefficacy
Bioefficacy asks whether the delivered ingredient produces a meaningful biological outcome. A formulation can improve dispersion without improving systemic exposure, or improve exposure without producing a superior clinical result.
For that reason, claims such as “better absorbed” should be supported by data for the exact formulation, not by general statements about liposomes.
What Does the Research Say About Liposomal Urolithin A?
Experimental liposome development
Researchers have prepared and characterized PEGylated Urolithin A liposomes and evaluated factors such as particle size, morphology, drug loading, release, cellular effects, and pharmacokinetic behavior (Yi et al., 2021). This work demonstrates that Urolithin A can be incorporated into liposomal systems, but a pharmaceutical-style PEGylated experimental formulation is not equivalent to every dietary supplement marketed as liposomal Urolithin A.
The frequently cited 1.91-fold result
Hu et al. (2023) developed Urolithin A liposomes using a pH-driven method and compared them with liposomes prepared by traditional thin-film dispersion. The pH-driven system showed favorable particle characteristics, encapsulation, stability, bioaccessibility, and rat pharmacokinetics. Its reported absorption efficiency was 1.91 times that of the traditional liposome formulation.
This result is often easy to misinterpret. It compared two liposomal preparation methods in rats. It did not demonstrate that a commercial liposomal supplement provides 1.91 times the bioavailability of regular Urolithin A in humans.
Additional research has examined how prebiotic saccharide coatings affect the encapsulation, stability, simulated digestion, and gut-microbiota interactions of Urolithin A liposomes (Hu et al., 2024). These results are useful for formulation development but do not establish clinical superiority.
Is there a human head-to-head comparison?
As of July 2026, the published evidence identified for this article does not include a direct human trial comparing an equal active dose of liposomal Urolithin A with regular Urolithin A. Therefore, it is not yet possible to give a universal human absorption ratio or state that every liposomal product is clinically better.
The evidence should be interpreted in this order:
- Human head-to-head clinical outcomes
- Human head-to-head pharmacokinetics
- Human evidence for one specific formulation
- Animal pharmacokinetics
- Simulated digestion and cell studies
- Physical characterization
- Unsupported marketing claims
Does Liposomal Urolithin A Have Better Bioavailability?
The scientifically responsible answer has three parts.
In theory: a well-designed liposome can improve Urolithin A dispersion, digestive stability, and delivery.
In preclinical research, certain systems have demonstrated promising bioaccessibility and pharmacokinetic performance.
In humans: direct comparative data are still needed before concluding that liposomal Urolithin A is consistently superior to regular Urolithin A.
Performance also varies between liposomal systems. Important variables include:
- Phospholipid source and composition
- Lipid-to-active ratio
- Actual Urolithin A loading
- Particle-size distribution
- Polydispersity index
- Surface charge
- Percentage of free and encapsulated active
- Vesicle structure
- Digestive stability
- Drying and reconstitution process
- Finished dosage form
- Packaging and storage conditions
Two products labeled “liposomal Urolithin A” may therefore perform very differently.
Do Both Forms Provide the Same Benefits?
Both forms are intended to deliver Urolithin A, so their active molecular target is the same. The phospholipid carrier does not create a different form of Urolithin A or automatically add a separate mitophagy effect.
Urolithin A is being studied for its ability to promote mitochondrial quality control, including mitophagy, the process by which damaged mitochondria are removed and recycled. Human research has also examined muscle strength, muscle endurance, physical performance, inflammatory biomarkers, and cellular energy-related pathways.
However, the outcomes demonstrated with one branded or research formulation should not automatically be transferred to another product. A liposomal formulation might produce stronger, similar, or weaker exposure depending on its design, active content, stability, and release characteristics.
Dosage: Compare Active Urolithin A, Not Complex Weight
One of the biggest practical problems in comparing products is unclear dose labeling.
A label may state:
- Milligrams of active Urolithin A
- Milligrams of liposomal Urolithin A powder
- Milligrams of phospholipid complex
- Total capsule fill weight
These numbers are not interchangeable. A 1,000 mg liposomal complex does not necessarily contain 1,000 mg of Urolithin A. For example, a complex could contain Urolithin A, phospholipids, carrier material, stabilizers, and moisture within the declared weight.
Brands and buyers should ask:
- How many milligrams of actual Urolithin A are delivered per serving?
- Is the assay reported on an as-is or dry basis?
- What is the active loading percentage?
- What percentage is encapsulated?
- How much remains unencapsulated?
- Is the declared dose verified in the finished product?
- Does the active remain within specification until the end of shelf life?
Do not claim that a lower liposomal dose is equivalent to 500 mg or 1,000 mg of regular Urolithin A unless a comparative study supports that equivalence.
Quality Control Requirements
Regular Urolithin A testing
A regular Urolithin A specification should address:
- Identity by an appropriate analytical method
- Urolithin A assay
- HPLC purity and related substances
- Residual starting materials and process impurities
- Residual solvents
- Elemental impurities
- Water content or loss on drying
- Microbial limits
- Particle size where relevant
- Stability and retest period
HPLC area purity should not be confused with total mass-balance purity. Water, residual solvents, inorganic material, and compounds with weak detector response may not be fully represented by a simple area-normalization result.
Additional liposomal quality testing
Liposomal Urolithin A requires the standard tests plus delivery-system characterization:
- Encapsulation efficiency
- Active loading capacity
- Free versus encapsulated Urolithin A
- Mean particle size and complete size distribution
- Polydispersity index
- Zeta potential
- Vesicle morphology
- Phospholipid identity and content
- Peroxide value or other lipid-oxidation indicators
- Leakage during storage
- Aggregation or fusion
- Release behavior
- Reconstitution performance for dry powders
- Simulated-digestion stability
Dynamic light scattering can help characterize size and PDI, while electron microscopy may aid in observing vesicles. Neither method alone proves bioavailability. Testing should be performed on the commercial material and, when relevant, on the finished capsules, tablets, liquids, or powders.
How to Verify Genuine Liposomal Urolithin A
Before purchasing a bulk liposomal ingredient, request answers to the following questions:
- Is the material a liquid liposome, dried liposome, proliposome, or phospholipid complex?
- What method demonstrates vesicle formation?
- What are the mean particle size, size distribution, and PDI?
- What is the encapsulation efficiency?
- What is the active loading percentage?
- How much active Urolithin A is present per gram?
- What phospholipid source is used?
- Is soy or another allergen present?
- Does a dry material reform vesicles after reconstitution?
- How do particle characteristics change during shelf life?
- Is the finished-product dose independently verified?
- Is there pharmacokinetic evidence for this exact formulation?
An image that appears to show spherical particles is not enough by itself. Buyers need a specification, methods, acceptance criteria, batch results, and stability data.
Stability and Shelf Life
Regular Urolithin A must be protected from unsuitable temperature, humidity, light, oxygen, and ingredient interactions. Appropriate packaging and storage should be based on stability data for the specific powder and final formulation.
Liposomes introduce additional risks:
- Vesicle aggregation or fusion
- Leakage of Urolithin A
- Phospholipid hydrolysis
- Lipid oxidation
- Changes in particle size or PDI
- Loss of vesicle structure during drying
- Incomplete or inconsistent reconstitution
Encapsulation may improve the stability of the active while making the overall delivery system more sensitive. Liquid products may need stronger oxygen, light, microbial, or temperature controls. Dry liposomal powders may require moisture-barrier packaging, desiccants, or protective atmospheres.
Brands should establish shelf life with a stability-indicating Urolithin A method and delivery-system measurements at relevant time points. Initial particle size alone does not prove that a product remains liposomal through expiry.
Provita also provides custom microencapsulation services for projects where stability, taste masking, controlled release, powder handling, or processing protection is more important than a conventional liposomal format.
Safety and Tolerability
Published toxicology work found a favorable safety profile for the tested Urolithin A material, including genotoxicity and repeated-dose assessments (Heilman et al., 2017). Short human trials have generally reported that oral Urolithin A was well tolerated, but these results apply to the tested materials, doses, durations, and populations.
Liposomal products also require evaluation of their excipients. Relevant considerations include:
- Soy or sunflower phospholipid source
- Allergen declarations
- Phospholipid oxidation
- Preservatives and antioxidants
- Carrier oils
- PEGylated materials, if used
- Processing aids and residual solvents
- Microbial control in liquid systems
Pregnant or breastfeeding individuals, people taking medication, and people with medical conditions should seek professional advice before using a Urolithin A supplement. This article is for ingredient and formulation education and is not medical advice.
Cost and Commercial Value
Liposomal Urolithin A usually costs more because it requires phospholipids, specialized processing, tighter process control, additional testing, stabilization, and sometimes more protective packaging.
The correct comparison is not price per kilogram of powder. Buyers should calculate:
- Price per kilogram of verified active Urolithin A
- Price per finished daily serving
- Active retention through shelf life
- Manufacturing loss and overage
- Evidence supporting the delivery claim
- Packaging and storage costs
- Finished-product testing requirements
The premium may be justified when the liposomal system provides documented dispersion, stability, sensory, processing, or pharmacokinetic benefits. Regular Urolithin A may provide better value when a straightforward capsule, tablet, or powder is sufficient and human research is the primary selling point.
Which Form Should Consumers Choose?
Regular Urolithin A may be the more rational choice when:
- The product delivers a clearly stated active dose.
- Human clinical evidence is the main priority.
- The brand provides identity, purity, potency, and contaminant testing.
- A simple formulation and lower cost are preferred.
Liposomal Urolithin A may be worth considering when:
- The active amount is clearly separated from total complex weight.
- The liposomal structure is properly characterized.
- Finished-product stability data are available.
- The delivery system offers a meaningful product-format advantage.
- Product-specific absorption data support the claims.
In either case, verified active content, formulation-specific evidence, manufacturing quality, and transparent labeling matter more than the delivery-system name.
Which Form Should Supplement Brands Choose?
Regular Urolithin A is well suited to capsules, tablets, sachets, powder blends, and cost-controlled formulas. It offers simpler sourcing, testing, processing, and label interpretation.
Liposomal Urolithin A may be suitable for premium healthy-aging products, sports nutrition, liquid shots, functional beverages, or differentiated mitochondrial-support formulas. Before choosing it, the development team should assess:
- Target active dose
- Available capsule or serving volume
- Compatibility with other ingredients
- Heat, pH, shear, and water exposure during processing
- Sensory impact
- Particle stability in the final matrix
- Required packaging
- Target-market regulatory requirements
- Evidence needed to support “liposomal” and bioavailability claims
Provita’s nutraceutical R&D services can support ingredient selection, dosage-form development, delivery-system design, pilot evaluation, and commercial scale-up.
How Liposomal Urolithin A Is Manufactured
A typical development process may include:
- Verify the identity, assay, purity, and particle characteristics of Urolithin A.
- Select phospholipids and define the lipid-to-active ratio.
- Dissolve or disperse the active and lipid materials.
- Form vesicles by hydration, injection, homogenization, microfluidization, or another validated method.
- Reduce and control particle size.
- Quantify free and encapsulated active.
- Stabilize the dispersion.
- Dry the material when a powder is required.
- Test active content and liposomal characteristics.
- Package under conditions supported by stability data.
Possible production methods include thin-film hydration, ethanol injection, high-pressure homogenization, ultrasonication, microfluidization, pH-driven encapsulation, spray drying, and freeze drying.
Critical process parameters may include pH, temperature, mixing rate, pressure, hydration time, lipid-to-active ratio, drying conditions, and oxygen exposure. Critical quality attributes include active assay, encapsulation efficiency, loading, particle size, PDI, zeta potential, vesicle integrity, oxidative stability, release, and microbial quality.
Regulatory and Labeling Considerations
“Liposomal” should accurately describe the material present in the product through its stated shelf life. Brands should not use an initial ingredient characterization to imply that vesicles remain intact after high-shear mixing, tableting, gummy cooking, beverage processing, or long-term storage without finished-product evidence.
Bioavailability and absorption claims require appropriate substantiation. Animal findings should be identified as animal findings, and simulated-digestion results should not be presented as clinical proof. Disease-treatment claims should be avoided for dietary supplements.
Labels and technical files should clearly state:
- Actual Urolithin A per serving
- Total liposomal complex where relevant
- Phospholipid and allergen source
- Other active ingredients
- Storage conditions
- Intended shelf life
- Market-appropriate warnings
The regulatory status of Urolithin A, excipients, nano-scale materials, claims, and dosage forms must be evaluated for each intended market.
About Provita Biotech
Provita Biotech is a China-based nutrition ingredient supplier and custom formulation partner serving supplement brands, contract manufacturers, importers, and distributors worldwide. The company combines raw material supply with delivery system development, finished-dose manufacturing, packaging, and export support.
For Urolithin A projects, Provita offers:
- Bulk Urolithin A powder with high-purity specifications and batch quality documentation
- Custom liposomal delivery development for improved dispersion, stability, and differentiated dosage forms
- Microencapsulation technology for protection, taste masking, controlled release, and powder performance
- OEM supplement manufacturing for custom capsules, tablets, and other finished formats
- Private-label support and custom packaging
- Formula development, dosage-form selection, brand design, packaging screening, and finished-product delivery
- Raw-material sourcing, quality documentation, and international logistics
Provita reports exporting approximately 100 metric tons of Urolithin A raw ingredients annually. This scale supports bulk supply, repeat orders, and commercial product development for healthy aging, mitochondrial health, and sports nutrition brands.
Provita operates quality and food safety management systems as described on its certifications and quality standards page. Buyers should request the current specification, Certificate of Analysis, manufacturing information, stability package, certifications, and market-specific regulatory documents for the exact Urolithin A ingredient or finished product being considered.
To discuss regular Urolithin A powder, custom liposomal Urolithin A, capsules, tablets, private-label products, or custom packaging, contact Provita Biotech for a formulation review and quotation.
Final Verdict
Regular Urolithin A currently has the stronger foundation of direct human evidence. It has demonstrated oral bioavailability and has been evaluated in controlled studies involving mitochondrial biomarkers, muscle strength, and muscle endurance. It is also easier to specify, manufacture, test, label, and price.
Liposomal Urolithin A has a credible scientific rationale and promising preclinical formulation data. It may improve dispersion, stability, bioaccessibility, or product-format performance when it is correctly designed. However, these advantages are formulation-specific. They cannot be assumed from the word “liposomal,” and direct human comparisons are still needed.
The best choice is the product that delivers a verified amount of Urolithin A, remains within specification through shelf life, and supports its claims with evidence relevant to the exact formulation.
Frequently Asked Questions
Is liposomal Urolithin A better than regular Urolithin A?
Not conclusively. Liposomal delivery may offer formulation and absorption advantages, but currently, regular Urolithin A has stronger direct evidence in humans. The performance of a liposomal product must be established for that specific formulation.
Does liposomal Urolithin A have higher bioavailability?
Certain experimental liposomal systems have shown improved bioaccessibility or pharmacokinetic performance in preclinical studies. A universal advantage over regular Urolithin A has not been established in direct human comparisons.
Is regular Urolithin A absorbed?
Yes. Human studies have detected circulating Urolithin A and its conjugated metabolites after direct oral supplementation.
Are there human trials on liposomal Urolithin A?
As of July 2026, we did not identify a published human head-to-head trial comparing liposomal and regular Urolithin A at equivalent active doses. Brands should check for new evidence and request product-specific studies from suppliers.
Is a phospholipid complex the same as a liposome?
No. A phospholipid complex may associate an active with phospholipids without forming closed vesicles. Liposomal claims should be supported by appropriate structural and particle-characterization data.
How much Urolithin A is in a liposomal complex?
It depends on the formulation. The total complex weight includes lipids and may include carriers or stabilizers. Buyers should request the actual Urolithin A content per gram and per serving.
Can a lower liposomal dose replace a higher regular dose?
Not without comparative evidence. A lower dose should not be described as equivalent to a clinically studied regular dose based only on theoretical absorption benefits.
What tests should a liposomal Urolithin A supplier provide?
At minimum, request active identity and assay, purity, contaminants, encapsulation efficiency, loading, free active, particle size, PDI, phospholipid information, oxidative stability, reconstitution data where relevant, and shelf-life results.
Does liposomal Urolithin A require refrigeration?
Not always. Storage depends on whether the product is liquid or dry, as well as on its composition, packaging, and stability data. Follow the manufacturer’s validated storage conditions.
Which form is better for capsules and tablets?
Regular Urolithin A is generally easier to use in high-dose capsules and tablets. Dry liposomal or proliposomal powders can also be used, but the brand should verify active loading, flow, compression compatibility, reconstitution behavior, and stability.
Which form is better for beverages?
A properly developed liposomal or other encapsulated system may offer better dispersion in a beverage. Compatibility with pH, heat, minerals, preservatives, proteins, and shelf-life conditions must be tested in the final beverage.
Is liposomal Urolithin A worth the extra cost?
It may be when product-specific data demonstrate a useful delivery, stability, sensory, or processing advantage. If the supplier cannot document these advantages, regular Urolithin A may provide better value.
References
Andreux, P. A., Blanco-Bose, W., Ryu, D., Burdet, F., Ibberson, M., Aebischer, P., Auwerx, J., Singh, A., & Rinsch, C. (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism, 1(6), 595–603. https://doi.org/10.1038/s42255-019-0073-4
Cerdá, B., Periago, P., Espín, J. C., & Tomás-Barberán, F. A. (2005). Identification of urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds. Journal of Agricultural and Food Chemistry, 53(14), 5571–5576. https://doi.org/10.1021/jf050384i
D’Amico, D., Andreux, P. A., Valdés, P., Singh, A., Rinsch, C., & Auwerx, J. (2021). Impact of the natural compound urolithin A on health, disease, and aging. Trends in Molecular Medicine, 27(7), 687–699. https://doi.org/10.1016/j.molmed.2021.04.009
Heilman, J., Andreux, P., Tran, N., Rinsch, C., & Blanco-Bose, W. (2017). Safety assessment of urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant-derived ellagitannins and ellagic acid. Food and Chemical Toxicology, 108, 289–297. https://doi.org/10.1016/j.fct.2017.07.050
Hodzic Kuerec, A., Lim, X. K., Khoo, A. L. Y., Sandalova, E., Guan, L., Feng, L., & Maier, A. B. (2024). Targeting aging with urolithin A in humans: A systematic review. Ageing Research Reviews, 99, 102406. https://doi.org/10.1016/j.arr.2024.102406
Hu, Y., Zhang, L., Wei, L.-F., Lu, F.-Y., Wang, L.-H., Ding, Q., Chen, M.-S., & Tu, Z.-C. (2023). Liposomes encapsulation by pH driven improves the stability, bioaccessibility and bioavailability of urolithin A: A comparative study. International Journal of Biological Macromolecules, 253, 127554. https://doi.org/10.1016/j.ijbiomac.2023.127554
Hu, Y., Zhang, L., Wen, Q.-H., Cheng, X.-P., Zhou, L.-Q., Chen, M.-S., & Tu, Z.-C. (2024). Prebiotic saccharides polymerization improves the encapsulation efficiency, stability, bioaccessibility and gut microbiota modulation of urolithin A liposomes. International Journal of Biological Macromolecules, 273, 133045. https://doi.org/10.1016/j.ijbiomac.2024.133045
Liu, S., D’Amico, D., Shankland, E., Bhayana, S., Garcia, J. M., Aebischer, P., Rinsch, C., Singh, A., & Marcinek, D. J. (2022). Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: A randomized clinical trial. JAMA Network Open, 5(1), e2144279. https://doi.org/10.1001/jamanetworkopen.2021.44279
Singh, A., D’Amico, D., Andreux, P. A., Dunngalvin, G., Kern, T., Blanco-Bose, W., Auwerx, J., Aebischer, P., & Rinsch, C. (2022a). Direct supplementation with urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. European Journal of Clinical Nutrition, 76(2), 297–308. https://doi.org/10.1038/s41430-021-00950-1
Singh, A., D’Amico, D., Andreux, P. A., Fouassier, A. M., Blanco-Bose, W., Evans, M., Aebischer, P., Auwerx, J., & Rinsch, C. (2022b). Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine, 3(5), 100633. https://doi.org/10.1016/j.xcrm.2022.100633
Yi, S., Zhang, C., Hu, J., Meng, Y., Chen, L., Yu, H., Li, S., Wang, G., Zheng, G., & Qiu, Z. (2021). Preparation, characterization, and in vitro pharmacodynamics and pharmacokinetics evaluation of PEGylated urolithin A liposomes. AAPS PharmSciTech, 22(1), 26. https://doi.org/10.1208/s12249-020-01890-y
